SCHEMBL25966751

SCHEMBL25966751

CCn1nc2cccnc2c1C(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
HTR2C P28335 5/20 0.35
HTR2A P28223 3/20 0.35
HTR2B P41595 3/20 0.35
KDM4E B2RXH2 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
SLC9A1 P19634 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
TNNI3 P19429 1/20 0.34
CRHBP P24387 1/20 0.34
MAPK1 P28482 1/20 0.34
CASP1 P29466 1/20 0.34
TNNT2 P45379 1/20 0.34
CASP7 P55210 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23067956 0.78 GRM4 (0.41) TLR8TLR7KDM4ETDP1MAPT
SCHEMBL23530096 0.78 SLC9A1 (0.41) HTR2CHTR2AHTR2BKDM4ETDP1
SCHEMBL25968043 0.77 MAOB (0.36) TLR8TLR7HTR2CHTR2AHTR2B
SCHEMBL25966752 0.75 MPO (0.45) KDM4ETDP1MAPTSLC9A1MEN1
SCHEMBL25966746 0.74 HTR2C (0.35) HTR2CKDM4EL3MBTL1KAT2BMAOB
SCHEMBL25966750 0.68 HASPIN (0.35) HTR2CHTR2AHTR2BATMKAT2B
SCHEMBL25966748 0.68 HASPIN (0.38) HTR2C
SCHEMBL20927208 0.65 L3MBTL1 (0.43) HTR2CMAPTL3MBTL1
SCHEMBL23529924 0.65 PDE1A (0.50) HTR2CHTR2AHTR2BSLC9A1L3MBTL1
SCHEMBL29549938 0.65 PDE1A (0.50) HTR2CHTR2AHTR2BSLC9A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 TLR8 58/4885TLR7 17/4885HTR2C 2900/4885
US-20230250088-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 TLR8 63/4885TLR7 20/4885HTR2C 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.